<DOC>
	<DOCNO>NCT01257386</DOCNO>
	<brief_summary>To demonstrate import Mesalazine ( AsacolÂ® ) non-inferior reference drug , market Mesalazine , regard primary endpoint ( reduction UC-DAI score ) patient active ulcerative colitis ( UC ) treat 8 week .</brief_summary>
	<brief_title>Comparative Efficacy Safety Study Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patients Ulcerative Colitis ( UC ) active phase define show Ulcerative ColitisDisease Activitiy Index ( UCDAI ) score 3 high 8 less , bloody stool score 1 high Patients serious high accord diagnostic critera seriousness patient chronic persistent type acute serious type classification clinical course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>